# Mario Delgado

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 180 papers | 11,603 citations | 64 h-index | 101 g-index |
| 189 ext. papers | 12,541 ext. citations | 6.5 avg, IF | 6.23 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 180 | Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. *Gastroenterology*, **2009**, 136, 978-89 | 13.3 | 486 |
| 179 | Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. *Gut*, **2009**, 58, 929-39 | 19.2 | 482 |
| 178 | Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. *Arthritis and Rheumatism*, **2009**, 60, 1006-19 | | 407 |
| 177 | Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. *Nature Medicine*, **2001**, 7, 563-8 | 50.5 | 334 |
| 176 | The significance of vasoactive intestinal peptide in immunomodulation. *Pharmacological Reviews*, **2004**, 56, 249-90 | 22.5 | 325 |
| 175 | Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2010**, 69, 241-8 | 9.4 | 311 |
| 174 | Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. *Gastroenterology*, **2003**, 124, 961-71 | 13.3 | 217 |
| 173 | Therapeutic action of ghrelin in a mouse model of colitis. *Gastroenterology*, **2006**, 130, 1707-20 | 13.3 | 208 |
| 172 | Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. *Tissue Engineering - Part A*, **2009**, 15, 2795-806 | 3.9 | 199 |
| 171 | Regulation of immune tolerance by anti-inflammatory neuropeptides. *Nature Reviews Immunology*, **2007**, 7, 52-63 | 36.5 | 181 |
| 170 | Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. *Gut*, **2013**, 62, 1131-41 | 19.2 | 157 |
| 169 | VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. *Journal of Neuroimmunology*, **1999**, 96, 167-81 | 3.5 | 147 |
| 168 | Immunology of VIP: a review and therapeutical perspectives. *Current Pharmaceutical Design*, **2001**, 7, 89-111 | 3.3 | 145 |
| 167 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. *Journal of Biological Chemistry*, **1998**, 273, 31427-36 | 5.4 | 138 |
| 166 | Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13562-7 | 11.5 | 137 |
| 165 | Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. *Journal of Experimental Medicine*, **2006**, 203, 563-71 | 16.6 | 134 |
| 164 | Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. *Journal of Molecular Medicine*, **2002**, 80, 16-24 | 5.5 | 133 |

| | | | |
|---|---|---|---|
| 163 | Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. *FASEB Journal*, **2003**, 17, 944-6 | 0.9 | 123 |
| 162 | Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. *Blood*, **2006**, 107, 3632-8 | 2.2 | 122 |
| 161 | Cell senescence abrogates the therapeutic potential of human mesenchymal stem cells in the lethal endotoxemia model. *Stem Cells*, **2014**, 32, 1865-77 | 5.8 | 119 |
| 160 | The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. *Journal of Immunology*, **2005**, 175, 7311-24 | 5.3 | 117 |
| 159 | Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 540-8 | 10.2 | 116 |
| 158 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. *Glia*, **2002**, 39, 148-61 | 9 | 116 |
| 157 | Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. *Journal of Immunology*, **2008**, 180, 8369-77 | 5.3 | 114 |
| 156 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. *Journal of Leukocyte Biology* , **1998**, 63, 591-601 | 6.5 | 114 |
| 155 | Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. *Critical Reviews in Oral Biology and Medicine*, **2002**, 13, 229-37 | | 113 |
| 154 | Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. *Journal of Immunology*, **2001**, 167, 966-75 | 5.3 | 107 |
| 153 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. *Journal of Leukocyte Biology*, **2003**, 73, 155-64 | 6.5 | 105 |
| 152 | Regulation of VIP production and secretion by murine lymphocytes. *Journal of Neuroimmunology*, **1999**, 93, 126-38 | 3.5 | 105 |
| 151 | Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. *Journal of Neuroimmunology*, **1996**, 68, 27-38 | 3.5 | 104 |
| 150 | Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 1053-8 | 11.5 | 103 |
| 149 | PACAP in immunity and inflammation. *Annals of the New York Academy of Sciences*, **2003**, 992, 141-57 | 6.5 | 101 |
| 148 | Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. *Amino Acids*, **2013**, 45, 25-39 | 3.5 | 97 |
| 147 | Immunobiology of vasoactive intestinal peptide (VIP). *Trends in Immunology*, **2000**, 21, 7-11 | | 97 |
| 146 | Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. *Stem Cells*, **2011**, 29, 251-62 | 5.8 | 94 |

| | | | |
|---|---|---|---|
| 145 | Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. *Brain, Behavior, and Immunity*, **2008**, 22, 1146-51 | 16.6 | 92 |
| 144 | Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. *Arthritis and Rheumatism*, **2006**, 54, 864-76 | | 89 |
| 143 | Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 4228-33 | 11.5 | 89 |
| 142 | Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. *FASEB Journal*, **2003**, 17, 1922-4 | 0.9 | 89 |
| 141 | VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. *FASEB Journal*, **2004**, 18, 1453-5 | 0.9 | 88 |
| 140 | Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. *Gut*, **2006**, 55, 824-32 | 19.2 | 86 |
| 139 | Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. *American Journal of Pathology*, **2006**, 168, 1179-88 | 5.8 | 86 |
| 138 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. *Journal of Biological Chemistry*, **2001**, 276, 369-80 | 5.4 | 86 |
| 137 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. *Journal of Biological Chemistry*, **1999**, 274, 31930-40 | 5.4 | 86 |
| 136 | Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?. *Journal of Immunology*, **2001**, 166, 2907-12 | 5.3 | 84 |
| 135 | Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. *Journal of Leukocyte Biology*, **2005**, 78, 1327-38 | 6.5 | 83 |
| 134 | Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. *Blood*, **2006**, 107, 3787-94 | 2.2 | 81 |
| 133 | Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. *Gastroenterology*, **2006**, 131, 1799-811 | 13.3 | 80 |
| 132 | The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. *FASEB Journal*, **2004**, 18, 1325-34 | 0.9 | 78 |
| 131 | Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. *European Journal of Immunology*, **2000**, 30, 3236-46 | 6.1 | 78 |
| 130 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. *Journal of Immunology*, **2001**, 166, 1028-40 | 5.3 | 77 |
| 129 | Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. *European Journal of Immunology*, **2006**, 36, 318-26 | 6.1 | 74 |
| 128 | Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. *Journal of Immunology*, **2000**, 165, 3051-7 | 5.3 | 74 |

| | | | |
|---|---|---|---|
| 127 | Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants. *PLoS ONE*, **2010**, 5, e13481 | 3.7 | 74 |
| 126 | Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. *Current Pharmaceutical Design*, **2007**, 13, 1113-39 | 3.3 | 72 |
| 125 | Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. *Glia*, **2008**, 56, 1091-103 | 9 | 71 |
| 124 | Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. *American Journal of Pathology*, **2006**, 168, 1921-30 | 5.8 | 71 |
| 123 | VIP modulation of immune cell functions. *Advances in Neuroimmunology*, **1996**, 6, 75-91 | | 69 |
| 122 | Preconditioning of microglia by □synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. *PLoS ONE*, **2013**, 8, e79160 | 3.7 | 69 |
| 121 | VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. *Journal of Neuroimmunology*, **1998**, 85, 155-67 | 3.5 | 68 |
| 120 | Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death. *Cell Death and Differentiation*, **2009**, 16, 406-16 | 12.7 | 67 |
| 119 | VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. *Journal of Leukocyte Biology*, **2004**, 75, 1122-30 | 6.5 | 67 |
| 118 | Human amnion favours tissue repair by inducing the M1-to-M2 switch and enhancing M2 macrophage features. *Journal of Tissue Engineering and Regenerative Medicine*, **2017**, 11, 2895-2911 | 4.4 | 66 |
| 117 | Therapeutic effect of human amniotic membrane-derived cells on experimental arthritis and other inflammatory disorders. *Arthritis and Rheumatology*, **2014**, 66, 327-39 | 9.5 | 65 |
| 116 | Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. *American Journal of Pathology*, **2008**, 172, 1297-307 | 5.8 | 62 |
| 115 | Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. *Journal of Biological Chemistry*, **2003**, 278, 27620-9 | 5.4 | 60 |
| 114 | VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. *Annals of the New York Academy of Sciences*, **1999**, 897, 401-14 | 6.5 | 60 |
| 113 | Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. *Annals of the Rheumatic Diseases*, **2007**, 66, 582-8 | 2.4 | 59 |
| 112 | Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. *Molecular Therapy*, **2010**, 18, 1035-45 | 11.7 | 58 |
| 111 | Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. *Trends in Molecular Medicine*, **2007**, 13, 241-51 | 11.5 | 58 |
| 110 | Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. *Arthritis and Rheumatism*, **2007**, 56, 531-43 | | 57 |

| | | | |
|---|---|---|---|
| 109 | Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. *Journal of Immunology*, **2006**, 176, 97-110 | 5.3 | 55 |
| 108 | Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. *Journal of Immunology*, **2001**, 167, 3182-9 | 5.3 | 55 |
| 107 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. *FASEB Journal*, **2002**, 16, 1844-6 | 0.9 | 54 |
| 106 | Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. *Annals of the New York Academy of Sciences*, **2000**, 921, 92-102 | 6.5 | 53 |
| 105 | miR-335 correlates with senescence/aging in human mesenchymal stem cells and inhibits their therapeutic actions through inhibition of AP-1 activity. *Stem Cells*, **2014**, 32, 2229-44 | 5.8 | 52 |
| 104 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. *Journal of Immunology*, **2000**, 164, 1200-10 | 5.3 | 51 |
| 103 | Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. *American Journal of Pathology*, **2007**, 170, 263-71 | 5.8 | 50 |
| 102 | Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. *Journal of Neuroimmunology*, **1996**, 68, 109-19 | 3.5 | 50 |
| 101 | Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. *Regulatory Peptides*, **1994**, 50, 177-84 | | 49 |
| 100 | Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **1997**, 1359, 250-62 | 4.9 | 48 |
| 99 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. *Biochemical and Biophysical Research Communications*, **2002**, 293, 771-6 | 3.4 | 48 |
| 98 | Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. *Advances in Neuroimmunology*, **1996**, 6, 29-36 | | 48 |
| 97 | VIP: a very important peptide in T helper differentiation. *Trends in Immunology*, **2003**, 24, 221-4 | 14.4 | 47 |
| 96 | Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. *Regulatory Peptides*, **1996**, 62, 161-6 | | 46 |
| 95 | Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. *Arthritis and Rheumatism*, **2008**, 58, 1010-9 | | 45 |
| 94 | Pituitary adenylate-cyclase-activating polypeptide expression in the immune system. *NeuroImmunoModulation*, **2002**, 10, 177-86 | 2.5 | 45 |
| 93 | Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. *Journal of Neuroimmunology*, **2000**, 110, 97-105 | 3.5 | 45 |
| 92 | Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP. *Journal of Neuroimmunology*, **1995**, 62, 137-46 | 3.5 | 45 |

| | | | |
|---|---|---|---|
| 91 | VIP gene expression in rat thymus and spleen. *Brain, Behavior, and Immunity*, **1993**, 7, 271-8 | 16.6 | 44 |
| 90 | Vasoactive intestinal peptide modulation of adherence and mobility in rat peritoneal lymphocytes and macrophages. *Peptides*, **1994**, 15, 1157-63 | 3.8 | 44 |
| 89 | Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases. *European Journal of Medicinal Chemistry*, **2018**, 146, 123-138 | 6.8 | 43 |
| 88 | Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation. *Circulation Research*, **2013**, 112, 1444-55 | 15.7 | 43 |
| 87 | Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?. *Trends in Pharmacological Sciences*, **2007**, 28, 482-91 | 13.2 | 43 |
| 86 | Immunotherapy for neurological diseases. *Clinical Immunology*, **2008**, 128, 294-305 | 9 | 42 |
| 85 | In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. *Arthritis and Rheumatism*, **2008**, 58, 1026-37 | | 42 |
| 84 | Gene expression of VIP receptor in rat lymphocytes. *Biochemical and Biophysical Research Communications*, **1994**, 203, 1599-604 | 3.4 | 42 |
| 83 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia. *Biochemical and Biophysical Research Communications*, **2002**, 297, 1181-5 | 3.4 | 41 |
| 82 | Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. *Peptides*, **1994**, 15, 791-8 | 3.8 | 39 |
| 81 | Differential VIP and VIP1 receptor gene expression in rat thymocyte subsets. *Peptides*, **1996**, 17, 803-7 | 3.8 | 38 |
| 80 | Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. *Journal of Neuroimmunology*, **1999**, 99, 61-71 | 3.5 | 37 |
| 79 | The neuropeptides VIP/PACAP and T cells: inhibitors or activators?. *Current Pharmaceutical Design*, **2003**, 9, 997-1004 | 3.3 | 37 |
| 78 | Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. *Brain, Behavior, and Immunity*, **2008**, 22, 35-41 | 16.6 | 36 |
| 77 | Mesenchymal stem cells induce the ramification of microglia via the small RhoGTPases Cdc42 and Rac1. *Glia*, **2014**, 62, 1932-42 | 9 | 35 |
| 76 | Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. *Biochemical and Biophysical Research Communications*, **2003**, 302, 275-83 | 3.4 | 35 |
| 75 | Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response. *PLoS ONE*, **2007**, 2, e1071 | 3.7 | 35 |
| 74 | Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis. *Cell Transplantation*, **2013**, 22, 839-54 | 4 | 34 |

| | | | |
|---|---|---|---|
| 73 | Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions. *NeuroImmunoModulation*, **1999**, 6, 97-107 | 2.5 | 34 |
| 72 | Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function in rat macrophages. Protein kinase C involvement. *Regulatory Peptides*, **1993**, 48, 345-53 | | 34 |
| 71 | N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. *World Journal of Gastroenterology*, **2008**, 14, 2851-7 | 5.6 | 34 |
| 70 | Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease. *Haematologica*, **2014**, 99, 1168-75 | 6.6 | 32 |
| 69 | Inhibitory neuropeptide receptors on macrophages. *Microbes and Infection*, **2001**, 3, 141-7 | 9.3 | 32 |
| 68 | Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. *Annals of the Rheumatic Diseases*, **2008**, 67, 1235-41 | 2.4 | 31 |
| 67 | Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens. *Journal of Biological Chemistry*, **2014**, 289, 14583-99 | 5.4 | 30 |
| 66 | Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. *Peptides*, **2007**, 28, 1833-46 | 3.8 | 30 |
| 65 | Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. *Current Opinion in Pharmacology*, **2010**, 10, 473-81 | 5.1 | 29 |
| 64 | VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. *Annals of the New York Academy of Sciences*, **2000**, 921, 55-67 | 6.5 | 29 |
| 63 | Pituitary adenylate cyclase-activating polypeptide (PACAP-38) stimulates rat peritoneal macrophage functions. *Peptides*, **1996**, 17, 1097-105 | 3.8 | 29 |
| 62 | Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility. *Neuropeptides*, **1996**, 30, 583-95 | 3.3 | 29 |
| 61 | A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells. *Journal of NeuroImmune Pharmacology*, **2006**, 1, 400-9 | 6.9 | 28 |
| 60 | Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. *Regulatory Peptides*, **2006**, 137, 67-74 | | 28 |
| 59 | VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. *Annals of the New York Academy of Sciences*, **2000**, 921, 68-78 | 6.5 | 28 |
| 58 | Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. *Archives of Physiology and Biochemistry*, **2001**, 109, 377-82 | 2.2 | 28 |
| 57 | Human bone marrow stromal cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation. *Stem Cell Reports*, **2014**, 3, 606-19 | 8 | 27 |
| 56 | Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function. *Stem Cells International*, **2017**, 2017, 2389753 | 5 | 27 |

| | | | |
|---|---|---|---|
| 55 | Vasoactive intestinal peptide: the dendritic cell --> regulatory T cell axis. *Annals of the New York Academy of Sciences*, **2006**, 1070, 233-8 | 6.5 | 27 |
| 54 | VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. *Annals of the New York Academy of Sciences*, **2006**, 1070, 276-81 | 6.5 | 27 |
| 53 | Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. *Biochemical and Biophysical Research Communications*, **2003**, 301, 825-32 | 3.4 | 27 |
| 52 | Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. *Journal of Neuroimmunology*, **2000**, 107, 88-99 | 3.5 | 27 |
| 51 | Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. *Journal of Immunology*, **2000**, 165, 114-23 | 5.3 | 27 |
| 50 | TH2 lymphocytes secrete functional VIP upon antigen stimulation. *Archives of Physiology and Biochemistry*, **2001**, 109, 365-8 | 2.2 | 26 |
| 49 | Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders. *Molecular and Cellular Endocrinology*, **2008**, 286, 135-40 | 4.4 | 25 |
| 48 | Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. *Annals of the Rheumatic Diseases*, **2007**, 66 Suppl 3, iii70-6 | 2.4 | 25 |
| 47 | Cortistatin attenuates inflammatory pain via spinal and peripheral actions. *Neurobiology of Disease*, **2014**, 63, 141-54 | 7.5 | 23 |
| 46 | Analysis of a GT microsatellite in the promoter of the foxp3/scurfin gene in autoimmune diseases. *Human Immunology*, **2005**, 66, 869-73 | 2.3 | 23 |
| 45 | Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP-1 and p38. *EMBO Journal*, **2014**, 33, 1117-33 | 13 | 22 |
| 44 | Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. *Annals of the New York Academy of Sciences*, **2006**, 1070, 337-41 | 6.5 | 22 |
| 43 | Regulation of dendritic cell differentiation by vasoactive intestinal peptide: therapeutic applications on autoimmunity and transplantation. *Annals of the New York Academy of Sciences*, **2006**, 1088, 187-94 | 6.5 | 22 |
| 42 | Analgesic effect of the neuropeptide cortistatin in murine models of arthritic inflammatory pain. *Arthritis and Rheumatism*, **2013**, 65, 1390-401 | | 20 |
| 41 | Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells. *Scientific Reports*, **2017**, 7, 46444 | 4.9 | 19 |
| 40 | LABCG2, a new ABC transporter implicated in phosphatidylserine exposure, is involved in the infectivity and pathogenicity of Leishmania. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2179 | 4.8 | 19 |
| 39 | Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 1830-47 | 5.6 | 19 |
| 38 | VIP: an agent with license to kill infective parasites. *Annals of the New York Academy of Sciences*, **2006**, 1070, 303-8 | 6.5 | 19 |

| | | | |
|---|---|---|---|
| 37 | Tuning inflammation with anti-inflammatory neuropeptides. *Expert Opinion on Biological Therapy*, **2007**, 7, 461-78 | 5.4 | 18 |
| 36 | Generating tolerogenic dendritic cells with neuropeptides. *Human Immunology*, **2009**, 70, 300-7 | 2.3 | 17 |
| 35 | Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo: therapeutic applications in autoimmunity and transplantation. *Annals of the New York Academy of Sciences*, **2006**, 1070, 190-5 | 6.5 | 17 |
| 34 | Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. *Experimental and Molecular Medicine*, **2017**, 49, e290 | 12.8 | 16 |
| 33 | Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune Responses. *Journal of Immunology*, **2018**, 200, 3697-3710 | 5.3 | 15 |
| 32 | Lulling immunity, pain, and stress to sleep with cortistatin. *Annals of the New York Academy of Sciences*, **2015**, 1351, 89-98 | 6.5 | 15 |
| 31 | Neuropeptides as therapeutic approach to autoimmune diseases. *Current Pharmaceutical Design*, **2010**, 16, 3158-72 | 3.3 | 15 |
| 30 | The neuropeptide cortistatin attenuates experimental autoimmune myocarditis via inhibition of cardiomyogenic T cell-driven inflammatory responses. *British Journal of Pharmacology*, **2017**, 174, 267-280 | 8.6 | 14 |
| 29 | VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors. *Archives of Physiology and Biochemistry*, **2001**, 109, 372-6 | 2.2 | 14 |
| 28 | VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells. *Journal of Neuroimmunology*, **2001**, 112, 78-88 | 3.5 | 12 |
| 27 | Cortistatin as a potential multistep therapeutic agent for inflammatory disorders. *Drug News and Perspectives*, **2006**, 19, 393-9 | | 10 |
| 26 | NPSR1 gene is associated with reduced risk of rheumatoid arthritis. *Journal of Rheumatology*, **2012**, 39, 1166-70 | 4.1 | 9 |
| 25 | Vasoactive intestinal peptide family as a therapeutic target for Parkinson's disease. *Expert Opinion on Therapeutic Targets*, **2005**, 9, 923-9 | 6.4 | 9 |
| 24 | Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in preclinical models of hematopoietic reconstitution and severe colitis. *Haematologica*, **2019**, 104, e54-e58 | 6.6 | 9 |
| 23 | Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. *Experimental Hematology*, **2017**, 45, 85-93.e2 | 3.1 | 8 |
| 22 | Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis. *BioMed Research International*, **2015**, 2015, 681456 | 3 | 8 |
| 21 | Vasoactive intestinal polypeptide induces regulatory dendritic cells that prevent acute graft versus host disease and leukemia relapse after bone marrow transplantation. *Annals of the New York Academy of Sciences*, **2006**, 1070, 226-32 | 6.5 | 8 |
| 20 | Role of Cortistatin in the Stressed Immune System. *Frontiers of Hormone Research*, **2017**, 48, 110-120 | 3.5 | 7 |

| | | | |
|---|---|---|---|
| 19 | Peripheral nerve reconstruction with epsilon-caprolactone conduits seeded with vasoactive intestinal peptide gene-transfected mesenchymal stem cells in a rat model. *Journal of Neural Engineering*, **2014**, 11, 046024 | 5 | 7 |
| 18 | Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease. *Nature Communications*, **2021**, 12, 1869 | 17.4 | 7 |
| 17 | VIP protects Th2 cells by downregulating granzyme B expression. *Annals of the New York Academy of Sciences*, **2006**, 1070, 540-4 | 6.5 | 5 |
| 16 | Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity **2020**, 8, | | 5 |
| 15 | The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia. *Journal of Neuroinflammation*, **2018**, 15, 343 | 10.1 | 5 |
| 14 | Ghrelin and adipose-derived mesenchymal stromal cells improve nerve regeneration in a rat model of epsilon-caprolactone conduit reconstruction. *Histology and Histopathology*, **2017**, 32, 627-637 | 1.4 | 4 |
| 13 | Therapeutic application of mesenchymal stromal cells in murine models of inflammatory bowel disease. *Methods in Molecular Biology*, **2014**, 1213, 331-9 | 1.4 | 4 |
| 12 | Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases. *European Journal of Medicinal Chemistry*, **2021**, 223, 113655 | 6.8 | 4 |
| 11 | Potential applications of vasoactive intestinal Peptide-based therapies on transplantation. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2012**, 12, 333-43 | 2.2 | 2 |
| 10 | Protective role of cortistatin in pulmonary inflammation and fibrosis. *British Journal of Pharmacology*, **2021**, 178, 4368-4388 | 8.6 | 2 |
| 9 | THE NEUROPEPTIDE CORTISTATIN REGULATES DERMAL AND PULMONARY FIBROSIS IN AN EXPERIMENTAL MODEL OF SYSTEMIC SCLEROSIS. *Neuroendocrinology*, **2021**, | 5.6 | 1 |
| 8 | The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury. *Pharmaceutics*, **2021**, 13, | 6.4 | 1 |
| 7 | Immunobiology of the Pituitary Adenylate Cyclase-Activating Peptide. *Current Topics in Neurotoxicity*, **2016**, 691-708 | | |
| 6 | Immunoregulatory Neuropeptides **2013**, 640-648 | | |
| 5 | PACAP **2013**, 1527-1534 | | |
| 4 | Role of Neuropeptides in T-Cell Differentiation **2004**, 289-304 | | |
| 3 | VIP and PACAP Immune Mediators Involved in Homeostasis and Disease **2004**, 263-283 | | |
| 2 | Vasoactive Intestinal Peptide: An Anti-inflammatory Neuropeptide **2007**, 131-157 | | |

1 Vasoactive Intestinal Peptide: Immune Mediator and Potential Therapeutic Agent **2012**, 257-288